Regulation and function of mTOR signalling in T cell fate decisions

Nature Reviews Immunology

Volumn 12, Issue 5, 2012, Pages 325-338

  Chi, Hongbo ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOPTOSIS SIGNAL REGULATING KINASE 1; EOMESODERMIN; FORKHEAD TRANSCRIPTION FACTOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 2; INTERLEUKIN 7; INTERLEUKIN 7 RECEPTOR ALPHA; LEPTIN; LEPTIN RECEPTOR; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; PROTEIN KINASE LKB1; RAPAMYCIN; RHEB PROTEIN; SMAD3 PROTEIN; SPHINGOSINE 1 PHOSPHATE RECEPTOR; STAT PROTEIN; STAT3 PROTEIN; STAT4 PROTEIN; STAT5 PROTEIN; STAT6 PROTEIN; TRANSCRIPTION FACTOR FKHR; TRANSCRIPTION FACTOR FOXP3; TRANSCRIPTION FACTOR GATA 3; TUMOR NECROSIS FACTOR RECEPTOR; UNINDEXED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANTIGEN RECOGNITION; AUTOIMMUNITY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL FATE; CELL FUNCTION; CELL MATURATION; CELL SURVIVAL; GENE ACTIVATION; GENE CONTROL; GENE EXPRESSION; GENE FUNCTION; GENE TARGETING; HELPER CELL; HUMAN; IMMUNE FUNCTION TEST; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; LYMPHOMA; METABOLIC REGULATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE; TH1 CELL; TH17 CELL; TH2 CELL;

ANIMALS; CELL LINEAGE; HUMANS; SIGNAL TRANSDUCTION; T-LYMPHOCYTES; TOR SERINE-THREONINE KINASES;

EID: 84860237060     PISSN: 14741733     EISSN: 14741741     Source Type: Journal    
DOI: 10.1038/nri3198     Document Type: Review

References (154)

1. Zoncu, R., Efeyan, A. & Sabatini, D. M. mTOR: from growth signal integration to cancer, diabetes and ageing. Nature Rev. Mol. Cell Biol. 12, 21-35 (2011).
2. Thomson, A. W., Turnquist, H. R. & Raimondi, G. Immunoregulatory functions of mTOR inhibition. Nature Rev. Immunol. 9, 324-337 (2009).
3. Araki, K., Ellebedy, A. H. & Ahmed, R. TOR in the immune system. Curr. Opin. Cell Biol. 23, 707-715 (2011).
4. Powell, J. D. & Delgoffe, G. M. The mammalian target of rapamycin: linking T cell differentiation, function, and metabolism. Immunity 33, 301-311 (2010).
5. Iwasaki, A. & Medzhitov, R. Regulation of adaptive immunity by the innate immune system. Science 327, 291-295 (2010).
6. Delgoffe, G. M. et al. The mTOR kinase differentially regulates effector and regulatory T cell lineage commitment. Immunity 30, 832-844 (2009).
7. Yang, K., Neale, G., Green, D. R., He, W. & Chi, H. The tumor suppressor Tsc1 enforces quiescence of naive T cells to promote immune homeostasis and function. Nature Immunol. 12, 888-897 (2011).
8. Wu, Q. et al. The tuberous sclerosis complex-mammalian target of rapamycin pathway maintains the quiescence and survival of naive T cells. J. Immunol. 187, 1106-1112 (2011).
9. O'Brien, T. F. et al. Regulation of T-cell survival and mitochondrial homeostasis by TSC1. Eur. J. Immunol. 41, 3361-3370 (2011).
10. Sancak, Y. et al. The Rag GTPases bind raptor and mediate amino acid signaling to mTORC1. Science 320, 1496-1501 (2008). (Pubitemid 351929429)
11. Sancak, Y. et al. Ragulator-Rag complex targets mTORC1 to the lysosomal surface and is necessary for its activation by amino acids. Cell 141, 290-303 (2010).
12. Gwinn, D. M. et al. AMPK phosphorylation of raptor mediates a metabolic checkpoint. Mol. Cell 30, 214-226 (2008). (Pubitemid 351626684)
13. Zheng, M. et al. Inactivation of Rheb by PRAK-mediated phosphorylation is essential for energy-depletion-induced suppression of mTORC1. Nature Cell Biol. 13, 263-272 (2011).
14. Wu, X. N. et al. Phosphorylation of Raptor by p38β participates in arsenite-induced mammalian target of rapamycin complex 1 (mTORC1) activation. J. Biol. Chem. 286, 31501-31511 (2011).
15. Zinzalla, V., Stracka, D., Oppliger, W. & Hall, M. N. Activation of mTORC2 by association with the ribosome. Cell 144, 757-768 (2011).
16. Oh, W. J. et al. mTORC2 can associate with ribosomes to promote cotranslational phosphorylation and stability of nascent Akt polypeptide. EMBO J. 29, 3939-3951 (2010).
17. Saci, A., Cantley, L. C. & Carpenter, C. L. Rac1 regulates the activity of mTORC1 and mTORC2 and controls cellular size. Mol. Cell 42, 50-61 (2011).
18. Turner, M. S., Kane, L. P. & Morel, P. A. Dominant role of antigen dose in CD4+Foxp3+ regulatory T cell induction and expansion. J. Immunol. 183, 4895-4903 (2009).
19. Katzman, S. D. et al. Duration of antigen receptor signaling determines T-cell tolerance or activation. Proc. Natl Acad. Sci. USA 107, 18085-18090 (2010).
20. Colombetti, S., Basso, V., Mueller, D. L. & Mondino, A. Prolonged TCR/CD28 engagement drives IL-2-independent T cell clonal expansion through signaling mediated by the mammalian target of rapamycin. J. Immunol. 176, 2730-2738 (2006).
21. Zheng, Y. et al. A role for mammalian target of rapamycin in regulating T cell activation versus anergy. J. Immunol. 178, 2163-2170 (2007). (Pubitemid 46233414)
22. Zheng, Y., Delgoffe, G. M., Meyer, C. F., Chan, W. & Powell, J. D. Anergic T cells are metabolically anergic. J. Immunol. 183, 6095-6101 (2009).
23. So, T., Choi, H. & Croft, M. OX40 complexes with phosphoinositide 3-kinase and protein kinase B (PKB) to augment TCR-dependent PKB signaling. J. Immunol. 186, 3547-3555 (2011).
24. Francisco, L. M. et al. PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J. Exp. Med. 206, 3015-3029 (2009).
25. Wofford, J. A., Wieman, H. L., Jacobs, S. R., Zhao, Y. & Rathmell, J. C. IL-7 promotes Glut1 trafficking and glucose uptake via STAT5-mediated activation of Akt to support T-cell survival. Blood 111, 2101-2111 (2008). (Pubitemid 351451522)
26. Rathmell, J. C., Farkash, E. A., Gao, W. & Thompson, C. B. IL-7 enhances the survival and maintains the size of naive T cells. J. Immunol. 167, 6869-6876 (2001). (Pubitemid 33144179)
27. Rao, R. R., Li, Q., Odunsi, K. & Shrikant, P. A. The mTOR kinase determines effector versus memory CD8+ T cell fate by regulating the expression of transcription factors T-bet and Eomesodermin. Immunity 32, 67-78 (2010).
28. Stephenson, L. M., Park, D. S., Mora, A. L., Goenka, S. & Boothby, M. Sequence motifs in IL-4Rα mediating cell-cycle progression of primary lymphocytes. J. Immunol. 175, 5178-5185 (2005). (Pubitemid 41456402)
29. Gulen, M. F. et al. The receptor SIGIRR suppresses Th17 cell proliferation via inhibition of the interleukin-1 receptor pathway and mTOR kinase activation. Immunity 32, 54-66 (2010).
30. Delgoffe, G. M. et al. The kinase mTOR regulates the differentiation of helper T cells through the selective activation of signaling by mTORC1 and mTORC2. Nature Immunol. 12, 295-303 (2011).
31. Zhou, J. et al. Activation of the PTEN/mTOR/STAT3 pathway in breast cancer stem-like cells is required for viability and maintenance. Proc. Natl Acad. Sci. USA 104, 16158-16163 (2007). (Pubitemid 350099378)
32. Lord, G. M. et al. Leptin modulates the T-cell immune response and reverses starvation-induced immunosuppression. Nature 394, 897-901 (1998). (Pubitemid 28410912)
33. Procaccini, C. et al. An oscillatory switch in mTOR kinase activity sets regulatory T cell responsiveness. Immunity 33, 929-941 (2010).
34. De Rosa, V. et al. A key role of leptin in the control of regulatory T cell proliferation. Immunity 26, 241-255 (2007). (Pubitemid 46329441)
35. Galgani, M. et al. Leptin modulates the survival of autoreactive CD4+ T cells through the nutrient/energy-sensing mammalian target of rapamycin signaling pathway. J. Immunol. 185, 7474-7479 (2010).
36. Liu, G. et al. The receptor S1P1 overrides regulatory T cell-mediated immune suppression through Akt-mTOR. Nature Immunol. 10, 769-777 (2009).
37. Liu, G., Yang, K., Burns, S., Shrestha, S. & Chi, H. The S1P1-mTOR axis directs the reciprocal differentiation of TH1 and Treg cells. Nature Immunol. 11, 1047-1056 (2010).
38. Geng, D. et al. When Toll-like receptor and T-cell receptor signals collide: a mechanism for enhanced CD8 T-cell effector function. Blood 116, 3494-3504 (2010).
39. Quigley, M., Martinez, J., Huang, X. & Yang, Y. A critical role for direct TLR2-MyD88 signaling in CD8 T-cell clonal expansion and memory formation following vaccinia viral infection. Blood 113, 2256-2264 (2009).
40. Rahman, A. H. et al. Antiviral memory CD8 T-cell differentiation, maintenance, and secondary expansion occur independently of MyD88. Blood 117, 3123-3130 (2011).
41. Ciofani, M. & Zuniga-Pflucker, J. C. Notch promotes survival of pre-T cells at the β-selection checkpoint by regulating cellular metabolism. Nature Immunol. 6, 881-888 (2005). (Pubitemid 43090442)
42. Sprent, J. & Surh, C. D. Normal T cell homeostasis: the conversion of naive cells into memory-phenotype cells. Nature Immunol. 12, 478-484 (2011).
43. Michalek, R. D. & Rathmell, J. C. The metabolic life and times of a T-cell. Immunol. Rev. 236, 190-202 (2010).
44. Suzuki, A. et al. T cell-specific loss of Pten leads to defects in central and peripheral tolerance. Immunity 14, 523-534 (2001). (Pubitemid 32520864)
45. Xue, L., Nolla, H., Suzuki, A., Mak, T. W. & Winoto, A. Normal development is an integral part of tumorigenesis in T cell-specific PTEN-deficient mice. Proc. Natl Acad. Sci. USA 105, 2022-2027 (2008). (Pubitemid 351439458)
46. Hagenbeek, T. J. & Spits, H. T-cell lymphomas in T-cell-specific Pten-deficient mice originate in the thymus. Leukemia 22, 608-619 (2008). (Pubitemid 351386732)
47. Finlay, D. K. et al. Phosphoinositide-dependent kinase 1 controls migration and malignant transformation but not cell growth and proliferation in PTEN-null lymphocytes. J. Exp. Med. 206, 2441-2454 (2009).
48. Guo, W. et al. Suppression of leukemia development caused by PTEN loss. Proc. Natl Acad. Sci. USA 108, 1409-1414 (2011).
49. Liu, X. et al. Distinct roles for PTEN in prevention of T cell lymphoma and autoimmunity in mice. J. Clin. Invest. 120, 2497-2507 (2010).
50. Hagenbeek, T. J. et al. The loss of PTEN allows TCRαβ lineage thymocytes to bypass IL-7 and pre-TCR-mediated signaling. J. Exp. Med. 200, 883-894 (2004). (Pubitemid 39362924)
51. Kishimoto, H. et al. The Pten/PI3K pathway governs the homeostasis of Vα14 iNKT cells. Blood 109, 3316-3324 (2007). (Pubitemid 46572519)
52. Di Cristofano, A. et al. Impaired Fas response and autoimmunity in Pten +-mice. Science 285, 2122-2125 (1999). (Pubitemid 29451429)
53. Sauer, S. et al. T cell receptor signaling controls Foxp3 expression via PI3K, Akt, and mTOR. Proc. Natl Acad. Sci. USA 105, 7797-7802 (2008). (Pubitemid 351872718)
54. Xiao, C. et al. Lymphoproliferative disease and autoimmunity in mice with increased miR-17-92 expression in lymphocytes. Nature Immunol. 9, 405-414 (2008). (Pubitemid 351405110)
55. Olive, V. et al. miR-19 is a key oncogenic component of mir-17-92. Genes Dev. 23, 2839-2849 (2009).
56. Jiang, S. et al. Molecular dissection of the miR-17-92 cluster's critical dual roles in promoting Th1 responses and preventing inducible Treg differentiation. Blood 118, 5487-5497 (2011).
57. Tamas, P. et al. LKB1 is essential for the proliferation of T-cell progenitors and mature peripheral T cells. Eur. J. Immunol. 40, 242-253 (2010).
58. Cao, Y. et al. The serine/threonine kinase LKB1 controls thymocyte survival through regulation of AMPK activation and Bcl-XL expression. Cell Res. 20, 99-108 (2010).
59. Cao, Y. et al. LKB1 regulates TCR-mediated PLCγ1 activation and thymocyte positive selection. EMBO J. 30, 2083-2093 (2011).
60. Maciver, N. J. et al. The liver kinase B1 is a central regulator of T cell development, activation, and metabolism. J. Immunol. 187, 4187-4198 (2011).
61. Mihaylova, M. M. & Shaw, R. J. The AMPK signalling pathway coordinates cell growth, autophagy and metabolism. Nature Cell Biol. 13, 1016-1023 (2011).
62. Tamas, P. et al. Regulation of the energy sensor AMP-activated protein kinase by antigen receptor and Ca2+ in T lymphocytes. J. Exp. Med. 203, 1665-1670 (2006). (Pubitemid 44036271)
63. Mayer, A., Denanglaire, S., Viollet, B., Leo, O. & Andris, F. AMP-activated protein kinase regulates lymphocyte responses to metabolic stress but is largely dispensable for immune cell development and function. Eur. J. Immunol. 38, 948-956 (2008).
64. Yilmaz, O. H. et al. Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells. Nature 441, 475-482 (2006). (Pubitemid 44050144)
65. Zhang, J. et al. PTEN maintains haematopoietic stem cells and acts in lineage choice and leukaemia prevention. Nature 441, 518-522 (2006). (Pubitemid 44050154)
66. Chen, C. et al. TSC-mTOR maintains quiescence and function of hematopoietic stem cells by repressing mitochondrial biogenesis and reactive oxygen species. J. Exp. Med. 205, 2397-2408 (2008).
67. Gan, B. et al. mTORC1-dependent and-independent regulation of stem cell renewal, differentiation, and mobilization. Proc. Natl Acad. Sci. USA 105, 19384-19389 (2008).
68. Gan, B. et al. Lkb1 regulates quiescence and metabolic homeostasis of haematopoietic stem cells. Nature 468, 701-704 (2010).
69. Gurumurthy, S. et al. The Lkb1 metabolic sensor maintains haematopoietic stem cell survival. Nature 468, 659-663 (2010).
70. Nakada, D., Saunders, T. L. & Morrison, S. J. Lkb1 regulates cell cycle and energy metabolism in haematopoietic stem cells. Nature 468, 653-658 (2010).
71. Peterson, T. R. et al. DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival. Cell 137, 873-886 (2009).
72. Budanov, A. V. & Karin, M. p53 target genes Sestrin1 and Sestrin2 connect genotoxic stress and mTOR signaling. Cell 134, 451-460 (2008).
73. Sancak, Y. et al. PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase. Mol. Cell 25, 903-915 (2007). (Pubitemid 46436534)
74. Vander Haar, E., Lee, S. I., Bandhakavi, S., Griffin, T. J. & Kim, D. H. Insulin signalling to mTOR mediated by the Akt/PKB substrate PRAS40. Nature Cell Biol. 9, 316-323 (2007). (Pubitemid 46344611)
75. Kerdiles, Y. M. et al. Foxo1 links homing and survival of naive T cells by regulating L-selectin, CCR7 and interleukin 7 receptor. Nature Immunol. 10, 176-184 (2009).
76. Ouyang, W., Beckett, O., Flavell, R. A. & Li, M. O. An essential role of the Forkhead-box transcription factor Foxo1 in control of T cell homeostasis and tolerance. Immunity 30, 358-371 (2009).
77. Lee, K. et al. Mammalian target of rapamycin protein complex 2 regulates differentiation of Th1 and Th2 cell subsets via distinct signaling pathways. Immunity 32, 743-753 (2010).
78. Sinclair, L. V. et al. Phosphatidylinositol-3-OH kinase and nutrient-sensing mTOR pathways control T lymphocyte trafficking. Nature Immunol. 9, 513-521 (2008). (Pubitemid 351560520)
79. Macintyre, A. N. et al. Protein kinase B controls transcriptional programs that direct cytotoxic T cell fate but is dispensable for T cell metabolism. Immunity 34, 224-236 (2011).
80. Gorentla, B. K., Wan, C. K. & Zhong, X. P. Negative regulation of mTOR activation by diacylglycerol kinases. Blood 117, 4022-4031 (2010).
81. Peter, C., Waldmann, H. & Cobbold, S. P. mTOR signalling and metabolic regulation of T cell differentiation. Curr. Opin. Immunol. 22, 655-661 (2010).
82. Araki, K., Youngblood, B. & Ahmed, R. The role of mTOR in memory CD8 T-cell differentiation. Immunol. Rev. 235, 234-243 (2010).
83. Finlay, D. & Cantrell, D. A. Metabolism, migration and memory in cytotoxic T cells. Nature Rev. Immunol. 11, 109-117 (2011).
84. Zhu, J., Yamane, H. & Paul, W. E. Differentiation of effector CD4 T cell populations. Annu. Rev. Immunol. 28, 445-489 (2010).
85. Shi, L. Z. et al. HIF1α-dependent glycolytic pathway orchestrates a metabolic checkpoint for the differentiation of TH17 and Treg cells. J. Exp. Med. 208, 1367-1376 (2011).
86. Dang, E. V. et al. Control of TH17/Treg balance by hypoxia-inducible factor 1. Cell 146, 772-784 (2011).
87. Bird, J. J. et al. Helper T cell differentiation is controlled by the cell cycle. Immunity 9, 229-237 (1998). (Pubitemid 28400036)
88. Wang, R. et al. The transcription factor Myc controls metabolic reprogramming upon T lymphocyte activation. Immunity 35, 871-882 (2011).
89. Jones, R. G. & Thompson, C. B. Revving the engine: signal transduction fuels T cell activation. Immunity 27, 173-178 (2007). (Pubitemid 47284920)
90. Pearce, E. L. Metabolism in T cell activation and differentiation. Curr. Opin. Immunol. 22, 314-320 (2010).
91. Frauwirth, K. A. et al. The CD28 signaling pathway regulates glucose metabolism. Immunity 16, 769-777 (2002). (Pubitemid 34786476)
92. Rathmell, J. C. T cell Myc-tabolism. Immunity 35, 845-846 (2011).
93. Michalek, R. D. et al. Estrogen-related receptor-α is a metabolic regulator of effector T-cell activation and differentiation. Proc. Natl Acad. Sci. USA 108, 18348-18353 (2011).
94. Gordan, J. D., Thompson, C. B. & Simon, M. C. HIF and c-Myc: sibling rivals for control of cancer cell metabolism and proliferation. Cancer Cell 12, 108-113 (2007). (Pubitemid 47199124)
95. DeBerardinis, R. J., Lum, J. J., Hatzivassiliou, G. & Thompson, C. B. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab. 7, 11-20 (2008).
96. Pearce, E. L. et al. Enhancing CD8 T-cell memory by modulating fatty acid metabolism. Nature 460, 103-107 (2009).
97. Michalek, R. D. et al. Cutting edge: distinct glycolytic and lipid oxidative metabolic programs are essential for effector and regulatory CD4+ T cell subsets. J. Immunol. 186, 3299-3303 (2011).
98. Sundrud, M. S. et al. Halofuginone inhibits TH17 cell differentiation by activating the amino acid starvation response. Science 324, 1334-1338 (2009).
99. Cui, G. et al. Liver X receptor (LXR) mediates negative regulation of mouse and human Th17 differentiation. J. Clin. Invest. 121, 658-670 (2011).
100. Duvel, K. et al. Activation of a metabolic gene regulatory network downstream of mTOR complex 1. Mol. Cell 39, 171-183 (2010).
101. Nicklin, P. et al. Bidirectional transport of amino acids regulates mTOR and autophagy. Cell 136, 521-534 (2009).
102. Grohmann, U. & Bronte, V. Control of immune response by amino acid metabolism. Immunol. Rev. 236, 243-264 (2010).
103. Cobbold, S. P. et al. Infectious tolerance via the consumption of essential amino acids and mTOR signaling. Proc. Natl Acad. Sci. USA 106, 12055-12060 (2009).
104. Munn, D. H. et al. GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase. Immunity 22, 633-642 (2005). (Pubitemid 40719198)
105. Cobbold, S. P., Adams, E., Nolan, K. F., Regateiro, F. S. & Waldmann, H. Connecting the mechanisms of T-cell regulation: dendritic cells as the missing link. Immunol. Rev. 236, 203-218 (2010).
106. Locasale, J. W. & Cantley, L. C. Metabolic flux and the regulation of mammalian cell growth. Cell Metab. 14, 443-451 (2011).
107. Lee, K., Won, H. Y., Bae, M. A., Hong, J. H. & Hwang, E. S. Spontaneous and aging-dependent development of arthritis in NADPH oxidase 2 deficiency through altered differentiation of CD11b+ and Th/Treg cells. Proc. Natl Acad. Sci. USA 108, 9548-9553 (2011).
108. Zhang, J. et al. The type III histone deacetylase Sirt1 is essential for maintenance of T cell tolerance in mice. J. Clin. Invest. 119, 3048-3058 (2009).
109. Beugnet, A., Tee, A. R., Taylor, P. M. & Proud, C. G. Regulation of targets of mTOR (mammalian target of rapamycin) signalling by intracellular amino acid availability. Biochem. J. 372, 555-566 (2003). (Pubitemid 36723901)
110. Choo, A. Y. et al. Glucose addiction of TSC null cells is caused by failed mTORC1-dependent balancing of metabolic demand with supply. Mol. Cell 38, 487-499 (2010).
111. Buchakjian, M. R. & Kornbluth, S. The engine driving the ship: metabolic steering of cell proliferation and death. Nature Rev. Mol. Cell Biol. 11, 715-727 (2010).
112. Mason, E. F. & Rathmell, J. C. Cell metabolism: An essential link between cell growth and apoptosis. Biochim. Biophys. Acta 1813, 645-654 (2011).
113. Battaglia, M., Stabilini, A. & Roncarolo, M. G. Rapamycin selectively expands CD4+CD25+FoxP3+ regulatory T cells. Blood 105, 4743-4748 (2005).
114. Strauss, L. et al. Selective survival of naturally occurring human CD4+CD25+Foxp3+ regulatory T cells cultured with rapamycin. J. Immunol. 178, 320-329 (2007). (Pubitemid 46033615)
115. Zeiser, R. et al. Differential impact of mammalian target of rapamycin inhibition on CD4+CD25+Foxp3+ regulatory T cells compared with conventional CD4+ T cells. Blood 111, 453-462 (2008).
116. Strauss, L., Czystowska, M., Szajnik, M., Mandapathil, M. & Whiteside, T. L. Differential responses of human regulatory T cells (Treg) and effector T cells to rapamycin. PLoS ONE 4, e5994 (2009).
117. Young, D. A. & Nickerson-Nutter, C. L. mTOR-beyond transplantation. Curr. Opin. Pharmacol. 5, 418-423 (2005).
118. Fernandez, D., Bonilla, E., Mirza, N., Niland, B. & Perl, A. Rapamycin reduces disease activity and normalizes T cell activation-induced calcium fluxing in patients with systemic lupus erythematosus. Arthritis Rheum. 54, 2983-2988 (2006). (Pubitemid 44497779)
119. Araki, K. et al. mTOR regulates memory CD8 T-cell differentiation. Nature 460, 108-112 (2009).
120. Ferrer, I. R. et al. Cutting edge: rapamycin augments pathogen-specific but not graft-reactive CD8+ T cell responses. J. Immunol. 185, 2004-2008 (2010).
121. Turner, A. P. et al. Sirolimus enhances the magnitude and quality of viral-specific CD8+ T-cell responses to vaccinia virus vaccination in rhesus macaques. Am. J. Transplant. 11, 613-618 (2011).
122. Li, Q. et al. A central role for mTOR kinase in homeostatic proliferation induced CD8+ T cell memory and tumor immunity. Immunity 34, 541-553 (2011).
123. Wang, Y., Wang, X. Y., Subjeck, J. R., Shrikant, P. A. & Kim, H. L. Temsirolimus, an mTOR inhibitor, enhances anti-tumour effects of heat shock protein cancer vaccines. Br. J. Cancer. 104, 643-652 (2011).
124. Chawla, A., Nguyen, K. D. & Goh, Y. P. Macrophage-mediated inflammation in metabolic disease. Nature Rev. Immunol. 11, 738-749 (2011).
125. Winer, S. et al. Normalization of obesity-associated insulin resistance through immunotherapy. Nature Med. 15, 921-929 (2009).
126. Nishimura, S. et al. CD8+ effector T cells contribute to macrophage recruitment and adipose tissue inflammation in obesity. Nature Med. 15, 914-920 (2009).
127. Feuerer, M. et al. Lean, but not obese, fat is enriched for a unique population of regulatory T cells that affect metabolic parameters. Nature Med. 15, 930-939 (2009).
128. Choo, A. Y., Yoon, S. O., Kim, S. G., Roux, P. P. & Blenis, J. Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation. Proc. Natl Acad. Sci. USA 105, 17414-17419 (2008).
129. O'Reilly, K. E. et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res. 66, 1500-1508 (2006). (Pubitemid 43259931)
130. Benjamin, D., Colombi, M., Moroni, C. & Hall, M. N. Rapamycin passes the torch: a new generation of mTOR inhibitors. Nature Rev. Drug Discov. 10, 868-880 (2011).
131. Apsel, B. et al. Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases. Nature Chem. Biol. 4, 691-699 (2008).
132. Feldman, M. E. et al. Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. PLoS Biol. 7, e38 (2009).
133. Thoreen, C. C. et al. An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. J. Biol. Chem. 284, 8023-8032 (2009).
134. Hsieh, A. C. et al. Genetic dissection of the oncogenic mTOR pathway reveals druggable addiction to translational control via 4EBP-eIF4E. Cancer Cell 17, 249-261 (2010).
135. Janes, M. R. et al. Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor. Nature Med. 16, 205-213 (2010).
136. Nath, N. et al. 5-aminoimidazole-4-carboxamide ribonucleoside: a novel immunomodulator with therapeutic efficacy in experimental autoimmune encephalomyelitis. J. Immunol. 175, 566-574 (2005). (Pubitemid 40884363)
137. Nath, N. et al. Metformin attenuated the autoimmune disease of the central nervous system in animal models of multiple sclerosis. J. Immunol. 182, 8005-8014 (2009).
138. Dunkle, A. & He, Y. W. Apoptosis and autophagy in the regulation of T lymphocyte function. Immunol. Res. 49, 70-86 (2011).
139. Haribhai, D. et al. A requisite role for induced regulatory T cells in tolerance based on expanding antigen receptor diversity. Immunity 35, 109-122 (2011).
140. Kang, J., Huddleston, S. J., Fraser, J. M. & Khoruts, A. De novo induction of antigen-specific CD4+CD25+Foxp3+ regulatory T cells in vivo following systemic antigen administration accompanied by blockade of mTOR. J. Leukoc. Biol. 83, 1230-1239 (2008). (Pubitemid 351960355)
141. Gao, W. et al. Contrasting effects of cyclosporine and rapamycin in de novo generation of alloantigen-specific regulatory T cells. Am. J. Transplant. 7, 1722-1732 (2007). (Pubitemid 46905432)
142. Haxhinasto, S., Mathis, D. & Benoist, C. The AKT-mTOR axis regulates de novo differentiation of CD4+Foxp3+ cells. J. Exp. Med. 205, 565-574 (2008). (Pubitemid 351439304)
143. Song, K., Wang, H., Krebs, T. L. & Danielpour, D. Novel roles of Akt and mTOR in suppressing TGF-β/ALK5-mediated Smad3 activation. EMBO J. 25, 58-69 (2006). (Pubitemid 43077295)
144. Ouyang, W. et al. Foxo proteins cooperatively control the differentiation of Foxp3+ regulatory T cells. Nature Immunol. 11, 618-627 (2010).
145. Harada, Y. et al. Transcription factors Foxo3a and Foxo1 couple the E3 ligase Cbl-b to the induction of Foxp3 expression in induced regulatory T cells. J. Exp. Med. 207, 1381-1391 (2010).
146. Kerdiles, Y. M. et al. Foxo transcription factors control regulatory T cell development and function. Immunity 33, 890-904 (2010).
147. Merkenschlager, M. & von Boehmer, H. PI3 kinase signalling blocks Foxp3 expression by sequestering Foxo factors. J. Exp. Med. 207, 1347-1350 (2010).
148. Seoane, J., Le, H. V., Shen, L., Anderson, S. A. & Massague, J. Integration of Smad and forkhead pathways in the control of neuroepithelial and glioblastoma cell proliferation. Cell 117, 211-223 (2004). (Pubitemid 38496241)
149. Zhang, N. & Bevan, M. J. CD8+ T cells: foot soldiers of the immune system. Immunity 35, 161-168 (2011).
150. Van der Windt, G. J. et al. Mitochondrial respiratory capacity is a critical regulator of CD8+ T cell memory development. Immunity 36, 68-78 (2012).
151. Hand, T. W. et al. Differential effects of STAT5 and PI3K/AKT signaling on effector and memory CD8 T-cell survival. Proc. Natl Acad. Sci. USA 107, 16601-16606 (2010).
152. Finlay, D. & Cantrell, D. Phosphoinositide 3-kinase and the mammalian target of rapamycin pathways control T cell migration. Ann. NY Acad. Sci. 1183, 149-157 (2010).
153. Koch, M. A. et al. The transcription factor T-bet controls regulatory T cell homeostasis and function during type 1 inflammation. Nature Immunol. 10, 595-602 (2009).
154. Taqueti, V. R. et al. T-bet controls pathogenicity of CTLs in the heart by separable effects on migration and effector activity. J. Immunol. 177, 5890-5901 (2006). (Pubitemid 44628802)